Abivax
Edit

Abivax

http://www.abivax.com/?lang=fr
Last activity: 07.02.2024
Categories: ExtensionMedTechOptimizeResearchBioTechDataDevelopmentDrug
Abivax is developing therapies that stimulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body’s natural immune system mechanisms to treat diseases. With several programs in clinical trials as well as in research and preclinical development, Abivax’s pipeline is strong and diversified addressing many unmet medical needs. Abivax is currently targeting different inflammatory diseases within its clinical trial program with lead compound ABX464: 1) Treatment Inflammatory Bowel Disease (IBD), specifically ulcerative colitis and Crohn's disease 2) Treatment of rheumatoid arthritis The second drug candidate, ABX196, is being tested in a clinical study for the treatment of liver cancer (HCC).
Followers
1.27K
Followers
4.55K
Mentions
52
Location: France, Ile-de-France, Paris
Employees: 11-50
Total raised: $299.85M
Founded date: 2013
Twitter
LinkedIn
Youtube
Email

Investors 2

Funding Rounds 5

DateSeriesAmountInvestors
22.02.2023-$141.57M-
22.07.2021-$94.35M-
29.10.2020-$32.7M-
13.10.2020-$17.68M-
15.02.2019-$13.56MSofinnova ...

Mentions in press and media 52

DateTitleDescriptionSource
07.02.2024Abivax appoints Ana Sharma as Vice President, Global Head of...Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024...einpresswi...
20.12.2023Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia...We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital fl...fiercebiot...
13.12.2023Sofinnova opens biotech creation ‘toolbox’ as part of Europe...Venture capital firm Sofinnova Partners has launched a new investment strategy specifically aimed at...fiercebiot...
16.11.2023'Optimism' at Jefferies conference, but don't expect biotech...When it comes to bringing together pharma and financiers, the U.S. leads the way with industrial-sca...fiercebiot...
23.10.2023Abivax Adds $236M to Show Its Anti-Inflammatory Med Can Stan...Abivax, a company whose ulcerative colitis drug is currently in late-stage clinical development, now...medcitynew...
19.04.2023Abivax Reports 2022 Financial Results and Operations UpdateObefazimod global pivotal phase 3 program (ABTECT program) in moderate to severe ulcerative colitis ...einpresswi...
22.02.2023Abivax Announces Successful Oversubscribed EUR 130M Cross-Ov...NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR TO U.S. PERSONS Abi...einpresswi...
22.02.2023Abivax announces successful oversubscribed EUR 130M cross-ov...-tcgcrossov...
22.02.2023Abivax Announces Successful Oversubscribed EUR 130M Cross-Ov...NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR TO U.S. PERSONS Abi...accesswire...
14.02.2023Abivax to Present Blood and Rectal Tissue Data from UC Patie...Abivax will be presenting a poster on blood and rectal tissue data from ulcerative colitis (UC) pati...accesswire...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In